Sunflower Pharmaceutical Group is a private pharmaceutical enterprise group focusing on Chinese patent medicine while highlighting chemical drugs and biologics. It’s also a group integrating the manufacturing, marketing and R&D of pharmaceutical products. At present, the group has 20 subsidiaries, including 10 drug manufacturing enterprises, 4 medical companies, 1 medicine research institute, 1 medicinal materials planting base,and 1 pharmaceutical packaging company. As of 2014, the company’s total assets had reached 3.733 billion yuan. It possesses altogether 15 dosage forms and 725 drug approval numbers, including one national herbal variety for protection, 12 exclusive varieties, 402 varieties included in the National Drug Reimbursement List and 181 essential drug varieties.
The group successfully went public on the Shenzhen Stock Exchange on December 30, 2014. The group is now a direct member enterprise of All-China Federation of Industry and Commerce, a member unit of China Chinese Medicine Association and a Major High-tech Enterprise of National Torch Program. In 2014, the group ranked among “Top 100 Enterprises in China's Pharmaceutical Industry”, “China's Top 50 Pharmaceutical Enterprises with Greatest Growth Potential” and “Top 20 Most Competitive Chinese Listed Pharmaceutical Companies”.
Hongling Pharma reached a strategic partnership with Sunflower in 2014. This partnership has a far-reaching influence on the future development of Honglin Pharma and lays a foundation for its brand upgrade.